REGENERON PHARMACEUTICALS, INC. Stock Issued During Period, Value, Restricted Stock Award, Gross
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2014-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2014-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, restricted stock award, gross for the quarter ending 2013-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, restricted stock award, gross for fiscal 2018 was $0.00.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, restricted stock award, gross for fiscal 2017 was $0.00.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, restricted stock award, gross for fiscal 2016 was $0.00.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, restricted stock award, gross for fiscal 2015 was $0.00.
| Period end | Stock Issued During Period, Value, Restricted Stock Award, Gross 3 month | Stock Issued During Period, Value, Restricted Stock Award, Gross 12 month |
|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-07 | |
| 2017-12-31 | $0.00 10-K · filed 2019-02-07 | |
| 2016-12-31 | $0.00 10-K · filed 2018-02-08 | |
| 2015-12-31 | $0.00 10-K · filed 2018-02-08 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $0.00 10-K · filed 2017-02-09 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $0.00 10-K · filed 2016-02-11 |
| 2012-12-31 | $0.00 10-K · filed 2015-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |